Egalet Added to Russell 3000, Russell 2000 and Russell Global Indexes

Egalet Added to Russell 3000, Russell 2000 and Russell Global Indexes

WAYNE, Pa., April 1, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT)
("Egalet"), a specialty pharmaceutical company developing and planning to
commercialize proprietary, abuse-deterrent oral products for the treatment of
pain and other indications, announced today that it was added to the Russell
3000®, Russell 2000® and Russell Global Indexes as part of Russell
Investments' first quarter IPO additions. The change to the indexes took
effect at the close of the U.S. markets yesterday Monday, March 31, 2014.

The Russell 2000® Index measures the performance of the small-cap segment of
the U.S. equity market and is a subset of the Russell 3000®, representing
approximately 10 percent of the total market capitalization of that index.
Membership in the Russell 2000® Index includes automatic inclusion in the
appropriate growth and style indexes. Russell Investments determines
membership for its equity indexes primarily by objective market-capitalization
rankings and style attributes.Russell indexes are widely used by investment
managers and institutional investors for index funds and as benchmarks for
both passive and active investment strategies and approximately $4.1 trillion
in assets are benchmarked to Russell Indexes.

About Egalet

Egalet Corporation is a specialty pharmaceutical company developing and
planning to commercialize proprietary, abuse-deterrent oral products for the
treatment of pain and other indications. Egalet has created two distinct drug
delivery systems, each with novel abuse-deterrent features and the ability to
control the release profile of the active pharmaceutical ingredient. Using its
proprietary platform, Egalet has developed a pipeline of clinical-stage,
opioid-based product candidates in tablet form that are specifically designed
to deter abuse by physical and chemical manipulation, while also providing
tailored release of the active pharmaceutical ingredient. Its lead product
candidate, Egalet-001, is an abuse-deterrent, extended-release, oral morphine
formulation in development for the treatment of moderate to severe chronic
pain. There are currently no commercially available abuse-deterrent
formulations of morphine, and if approved, Egalet believes that Egalet-001
would fill a significant unmet need in the marketplace. Its second product
candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone
formulation in development for the treatment of moderate to severe chronic
pain. The Egalet technology can be applied broadly across different classes of
pharmaceutical products and can be used to develop combination products that
include multiple APIs with similar or different release profiles. Visit
www.egalet.com for more information.

Safe Harbor

Statements included in this press release that are not historical in nature
are "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are based on
management's current expectations, and are subject to known and unknown
uncertainties and risks.Actual results could differ materially from those
discussed due to a number of factors, including, but not limited to: the
success of our clinical trials; our ability to obtain regulatory approval of
our product candidates; competitive factors; general market conditions; and
other risks factors described in Egalet's filings with the United States
Securities and Exchange Commission. Egalet assumes no obligation to update or
revise any forward-looking-statements contained in this press release whether
as a result of new information or future events, except as may be required by
law.

CONTACT: E. Blair Clark-Schoeb
         Tel: 917-432-9275
         Email: blair@biotechcomm.com

Egalet Corporation Logo
 
Press spacebar to pause and continue. Press esc to stop.